Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
F
FRE
vs
S
S&P/ASX 300
Over the past 12 months, FRE has underperformed S&P/ASX 300, delivering a return of -59% compared to S&P/ASX 300's 4% drop.
Stocks Performance
FRE vs S&P/ASX 300
Performance Gap
FRE vs S&P/ASX 300
Performance By Year
FRE vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Firebrick Pharma Ltd
Glance View
Firebrick Pharma Ltd. is a pharmaceutical company, which engages in the development and commercialization of nasal spray treatment for the common cold based around the potential of povidone-iodine as an antimicrobial agent. The company is headquartered in Melbourne, Victoria. The company went IPO on 2022-01-28. The principal activity for the Company is the clinical development and partnering of Nasodine, a broad-spectrum antimicrobial spray for the treatment of the common cold. The firm has developed a povidone-iodine nasal spray, called Nasodine Nasal Spray and filed international trademarks and multiple patents on the product, including a formulation patent and two use patents, some of which have already been granted in the United States, Europe and Australia. The firm has also completed six clinical trials for Nasodine, including a Phase I study, three Phase II studies and two Phase III studies, which have affirmed the product’s safety and generally supported its efficacy as an antimicrobial nasal spray with utility in a range of clinical settings. Nasodine Phase II COVID-19 trail achieves primarily endpoints.